Perigon Wealth Management LLC Sells 340 Shares of Edwards Lifesciences Co. (NYSE:EW)

Perigon Wealth Management LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 9.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,226 shares of the medical research company’s stock after selling 340 shares during the period. Perigon Wealth Management LLC’s holdings in Edwards Lifesciences were worth $267,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of EW. Marshall Wace LLP lifted its position in Edwards Lifesciences by 167.5% during the third quarter. Marshall Wace LLP now owns 3,512,312 shares of the medical research company’s stock valued at $290,225,000 after purchasing an additional 2,199,410 shares in the last quarter. FMR LLC lifted its position in Edwards Lifesciences by 16.3% during the second quarter. FMR LLC now owns 8,861,392 shares of the medical research company’s stock valued at $842,630,000 after purchasing an additional 1,244,420 shares in the last quarter. Artisan Partners Limited Partnership purchased a new position in Edwards Lifesciences during the third quarter valued at $78,726,000. Voya Investment Management LLC lifted its position in Edwards Lifesciences by 305.3% during the second quarter. Voya Investment Management LLC now owns 1,218,590 shares of the medical research company’s stock valued at $115,875,000 after purchasing an additional 917,906 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Edwards Lifesciences by 19.0% during the second quarter. Massachusetts Financial Services Co. MA now owns 5,381,049 shares of the medical research company’s stock valued at $511,685,000 after purchasing an additional 860,313 shares in the last quarter. Institutional investors own 80.35% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $78.00, for a total transaction of $312,000.00. Following the sale, the vice president now directly owns 18,911 shares of the company’s stock, valued at $1,475,058. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, VP Daveen Chopra sold 4,000 shares of the business’s stock in a transaction on Tuesday, January 17th. The stock was sold at an average price of $78.00, for a total transaction of $312,000.00. Following the completion of the transaction, the vice president now owns 18,911 shares in the company, valued at approximately $1,475,058. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 19,875 shares of the business’s stock in a transaction on Friday, January 13th. The shares were sold at an average price of $78.09, for a total value of $1,552,038.75. Following the transaction, the chief executive officer now owns 157,353 shares of the company’s stock, valued at approximately $12,287,695.77. The disclosure for this sale can be found here. Insiders have sold 101,821 shares of company stock valued at $7,902,704 over the last ninety days. 1.29% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Mizuho lowered their target price on Edwards Lifesciences from $100.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, December 7th. Canaccord Genuity Group boosted their price objective on Edwards Lifesciences from $68.00 to $76.00 and gave the company a “hold” rating in a research report on Wednesday, February 1st. Wells Fargo & Company downgraded Edwards Lifesciences from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $97.00 to $78.00 in a research report on Wednesday, March 8th. Piper Sandler downgraded Edwards Lifesciences from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $95.00 to $80.00 in a research report on Monday, January 30th. Finally, Raymond James downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Monday, February 6th. One analyst has rated the stock with a sell rating, ten have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $88.95.

Edwards Lifesciences Trading Down 1.4 %

Shares of NYSE EW opened at $80.74 on Friday. The business’s 50 day moving average is $78.35 and its two-hundred day moving average is $79.39. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.03 and a quick ratio of 2.17. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $131.10. The stock has a market capitalization of $48.94 billion, a P/E ratio of 33.09, a PEG ratio of 4.63 and a beta of 1.01.

Edwards Lifesciences (NYSE:EW – Get Rating) last issued its quarterly earnings data on Tuesday, January 31st. The medical research company reported $0.64 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.03. Edwards Lifesciences had a return on equity of 26.05% and a net margin of 28.27%. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.33 billion. During the same period in the previous year, the firm posted $0.51 earnings per share. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. As a group, research analysts expect that Edwards Lifesciences Co. will post 2.52 EPS for the current year.

Edwards Lifesciences Profile

(Get Rating)

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.